BlueStone Venture Partners


BlueStone Venture Partners is a Southwest‑rooted, life sciences venture capital firm that invests in early‑stage companies outside traditional US innovation hubs. The firm focuses on transformative platforms in Medical Devices, Diagnostics, Digital Health and Life Science Research Tools, providing growth capital, hands‑on strategic support, and access to industry partners and co‑investors.

BlueStone Venture Partners

Tucson, Arizona, United States, North America


Services

Growth Capital (Equity)

Provides growth capital to early‑stage life sciences companies; typical check sizes between $250,000 and $1,000,000. Willing to lead or co‑lead rounds.

Strategic and Operational Support

Hands‑on management and strategic planning support for portfolio companies, leveraging the team's operational and technical backgrounds.

Diligence & Research Support

Dedicated research and diligence execution to evaluate potential investments and support portfolio company milestones.

Network and Partner Access

Provides privileged access to strategic partners including investors, customers, advisors, and supply‑chain partners through existing deal pipelines and relationships.

Board Participation and Governance

Seeks a board seat as part of investments to provide governance and strategic oversight.


Portfolio

Referenced on BlueStone portfolio page; news item on securing financing to advance a cell separation platform.

#Life science tools (cell separation)

Referenced on BlueStone portfolio page; received U.S. 510(k) clearance for PlaqueIQ image analysis software.

#Cardiovascular imaging / medical software

Referenced on BlueStone portfolio page; multiple financing and regulatory milestones reported related to GammaTile therapy.

#Medical devices (GammaTile radiation therapy)

Referenced on BlueStone portfolio page; announced commercial availability of NTxscribe and plans for a biomanufacturing facility.

#Biomanufacturing / RNA enabling technologies

Referenced on BlueStone portfolio page; noted acquisition by Exact Sciences in site news.

#Diagnostics

Referenced on BlueStone portfolio page; received FDA Breakthrough Device designation for DCISionRT test.

#Diagnostics (breast cancer risk test)

View All Portfolio Items

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.